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Despite the fact that allogeneic red blood cell (RBC) trans-
fusions can be life-saving in exsanguinating trauma pa-
tients, many adverse events impacting patient outcome
have documented [1]. Therefore, artificial oxygen carriers
were initially been developed as “blood substitutes” in the
1980s and 1990s. Artificial oxygen carriers can be grouped
into hemoglobin-based oxygen carriers (HBOCs) and
perfluorocarbon-based oxygen carriers (PFCs) [2].
The clinical use of artificial oxygen carriers has mainly
been studied in trauma and major surgery [3]. HBOC stud-
ies in general did not show a benefit in the primary out-
come parameter such as avoidance/reduction of RBC
transfusions or 28-day mortality [3] and signs of vasocon-
striction/hypertension due to nitric oxide scavenging and
increased relative risk of myocardial infarction and death
were shown in a meta-analysis [4]. Consequently, the Food
and Drug Agency in 2008 put all HBOC trials on hold.
PFC studies in non-cardiac surgery were successful in
reversing physiologic transfusion triggers and in redu-
cing the need for allogeneic RBC transfusions [5]. In
addition, there were no major safety issues. However, a
PFC study in cardiac surgery was prematurely stopped
due to an increased incidence of neurologic adverse
events, and this program has never been re-started.
In recent years, focus on the potential clinical use of arti-
ficial oxygen carriers moved away from “blood substitutes”
towards “oxygen therapeutics”. Due to the relatively short
half-life of 12–24 h, this may indeed be reasonable. How-
ever, clinical studies showing clear benefits in this new area
are still scarce. The area with most documented evidence
are “compassionate use” programs. In such programs, pa-
tients were treated with HBOCs at a median hemoglobin
concentration of 39 g/l [6]. Survival of patients with severe
anemia for whom RBC transfusion was not an option was
clearly and significantly higher if treated with an HBOC [7].
It is also conceivable that an HBOC may be capable of
bridging a patient with severe anemia until RBC transfu-
sions become available.
In animal models, artificial oxygen carriers have also
proven to be efficacious in relieving organ ischemia such
as fetal hypoxia in pre-eclampsia [8] and cerebral ische-
mia [9]. However, in a recent study myocardial perfusion
with an oxygenated HBOC-enriched solution did not re-
duce the infarct volume nor was post-ischemic cardiac
function improved [10]. In contrast, HBOC attenuated
intense exercise-induced cardiac dysfunction [11].
Machine perfusion of liver grafts after prolonged cold is-
chemia with HBOC enriched perfusate appears to be effica-
cious in improving the condition of the liver graft prior to
transplantation in multiple animal experiments [12]. And
recently the first human liver transplantation after machine
perfusion with HBOC was performed.1 The use of artificial
oxygen carriers in pre-transplant perfusion is also conceiv-
able in other organs such as lung and heart. The future will
tell whether HBOCs or PFCs are more efficacious.
PFCs may also be used as contrast agents [13] and, in
conjunction with magnetic resonance imaging, as infection
tracers [14].
Finally yet importantly, artificial oxygen carriers look like
a logical adjunct to Patient Blood Management. Patient
Blood Management is already highly successful: a reduction
in the use of allogeneic blood product transfusion of ap-
proximately 40%, a decrease in hospital mortality (−28%),
infection rate (−21%), combined myocardial infarction and
stroke (−31%), length of hospital stay (−15%), and annual
costs ($7–29 million) has been described in a study on
605,000 patients in Western Australia [15]. Nevertheless,
having an artificial oxygen carrier to bridge the period of
low hemoglobin/hematocrit or in the context of augmented
hemodilution [5] might broaden the spectrum of Patient
Blood Management and may make it even more successful.
Artificial oxygen carriers thus may indeed have a new
future in a large variety of clinical scenarios and diagnos-
tic/therapeutic concepts.
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